Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Valsoft Corporation Strengthens Its Retail Software Portfolio with the Acquisition of NedFox2.4.2026 15:00:00 CEST | Press release
MONTRÉAL, QC / ACCESS Newswire / April 2, 2026 / Valsoft Corporation Inc. ("Valsoft"), a Montreal-based company specializing in the acquisition and development of vertical market software businesses, is pleased to announce the acquisition of NedFox, the Netherlands-based software producer of RetailVista, a comprehensive Retail ERP platform designed to support modern retail operations. Headquartered in the Netherlands, NedFox develops and markets RetailVista, an integrated cloud-based Retail ERP solution that enables retailers to manage point-of-sale, inventory, purchasing, financial administration, and reporting within a unified environment. With a strong focus on continuous innovation and customer-driven development, NedFox has built a reputation for delivering reliable, scalable software tailored to the evolving needs of retail businesses. "NedFox has built a robust and highly regarded Retail ERP platform with RetailVista, supported by a passionate team and a strong customer focus,"
Side-by-Side Conference Hosts Close to 800 Participants in Malta to Advance Women's Health Care2.4.2026 14:10:00 CEST | Press release
Gedeon Richter's Side-by-Side Conference on Advancing Women's Health brought together Healthcare practitioners from 40 countries for a dynamic two-day exchange on March 26-27, making it the largest event of its kind ever organized by the company. BUDAPEST, HU / ACCESS Newswire / April 2, 2026 / Developed in collaboration with internationally recognized experts and grounded in peer-reviewed data, the program provided evidence-based updates on recent advances and innovations across key therapeutic areas, underscoring scientific integrity and evidence-based discussions. Beyond the science, the conference brought into focus how effective communication between healthcare professionals and patients can lead to improved diagnostic accuracy, treatment adherence, and overall patient satisfaction, as emphasized during his keynote lecture by Sukhbir Sony Singh, Full Professor and Chair of the Department of Obstetrics and Gynecology at the University of Ottawa. Day 1 focused on endometriosis and u
U.S. Polo Assn. Supports Division I National Intercollegiate Championship, Showcasing the Future of the Sport of Polo2.4.2026 13:00:00 CEST | Press release
DI Women's and Men's Finals to be Featured in ‘Breakaway: Polo in College' on ESPN WEST PALM BEACH, FLA. / ACCESS Newswire / April 2, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly supported the Division I National Intercollegiate Championship (NIC), held March 19-22, 2026, near Dallas, Texas, at the Prestonwood Polo & Country Club. As the highest level of collegiate polo in the United States, the NIC brings together the nation's top student-athletes to compete for national titles.2026 Division I Women's National Intercollegiate Champions, University of South Carolina - Aiken Polo Team Winifred Branscum, Madison Jordan, and Brianna Jordan; 2026 Division I Men's National Intercollegiate Champions, University of North Texas Polo Team Alec Felhaber, Niklaus Felhaber, Johann Felhaber, Mosiah Gravesande, Sebastian Celis Guerrero Photo Credit: @oanaphoto As a proud supporter of the USPA's Intercollegiate/Interscholastic (I/I) Program,
Datavault AI Inc. (NASDAQ: DVLT) and Demora Foundation Execute Technology Integration Agreement to Power the K-Entertainment & K-Wave Global Platform1.4.2026 17:50:00 CEST | Press release
DVLT × Demora Foundation: Datavault AI's Enterprise AI Stack Deployed as the Data Intelligence & RWA Tokenization Layer for K-Pop, K-Drama, K-Entertainment, and K-Culture IP - Serving 200M+ Hallyu Fans Across 156 Countries Through K2Global's 500+ Korean SMB Network and Three US Innovation K-Wave Cities PHILADELPHIA, PA AND WILMINGTON, DE / ACCESS Newswire / April 1, 2026 / Datavault AI Inc. (NASDAQ:DVLT), an AI-driven data monetization, RWA tokenization, and Web 3.0 infrastructure company, and Demora Foundation, the Delaware-incorporated governing organization of the Demora Chain ecosystem (governed under JP3E Holdings Inc.), today announced the execution of a Technology Integration Agreement establishing Datavault AI as the formal AI data intelligence and RWA tokenization technology partner for the K-Entertainment & K-Wave Global Platform - the integrated K2Global + Demora Foundation ecosystem that converts Korean cultural IP, live entertainment, and K-Wave soft power into institution
Stagwell Announces UNICEPTA UK and Hootsuite Strategic Partnership to Deliver Decision-Grade Media Intelligence Within the Talkwalker Platform1.4.2026 17:00:00 CEST | Press release
Bringing together advanced technology and social insights to provide enterprise-ready, decision-grade media intelligence. LONDON, GB / ACCESS Newswire / April 1, 2026 / Stagwell (NASDAQ:STGW), the global challenger network transforming marketing through AI, today announced a strategic partnership between UNICEPTA, Stagwell's global provider of human-led, AI-fed media intelligence, and Hootsuite for their UK business. The collaboration integrates UNICEPTA UK's specialist media intelligence services into Hootsuite's Talkwalker platform environment, strengthening the intelligence capabilities available to communications leaders operating in complex, high-stakes environments. "Many FTSE 100 organisations already trust the combined UNICEPTA and Talkwalker solution. Our partnership with Hootsuite builds on that foundation - bringing together enterprise-level social intelligence with UNICEPTA's global content platform and managed services to deliver faster, more consistent and more actionable
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom